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Gene Variant Predicted Association P OR CI95%
VCAM1
rs1409419_T  TAMMV 0.010 4.705 1.566-14.132
haplotype 7  TAMMV 0.010 4.705 1.566-14.132
ITGA4
rs113276800_A Stroke 0.025 7.619 1.394-41.653
rs3770138_T
Stroke 0.045 5.571 1.122-27.665
Cerebral vasculopathy 0.017 7.615 1.358-42.707
NOS3
VNTR 27 bp _ 4b allele
Silent cerebral infarcts 
Protective
0.041 0.114 0.016-0.808
haplotype 5
Silent cerebral infarcts 
Protective
0.009 0.13 0.029-0.582
haplotype 7
Cerebral vasculopathy
Protective
0.015 0.084 0.010-0.691
ENPP1 rs1044498_A  TAMMV 0.040 4.025 1.207-13.418
Sickle cell anaemia (SCA) arises from homozygosity
for the mutation c.20A>T in the HBB gene. However,
it shows a multifactorial-like behavior with high
heterogeneity of clinical features1. Cerebral
vasculopathy (CVA) constitutes a severe
complication of SCA, especially in children, and
comprises a spectrum of clinical manifestations that
includes overt stroke, transient ischemic attacks,
silent cerebral infarcts (SCIs), and frequent cognitive
decline 2,3,4. The risk of stroke development as well as
of other CVA events, such as SCIs, may be
modulated by underlying genetic modifiers, namely
those affecting vascular homeostasis.
1. Introduction 4. Results and Discussion
2. Aims
• Investigate the role of variants in genes related 
with endothelial adhesion (VCAM1 and ITGA4)
and nitric oxide metabolism (NOS3) on CVA 
events in SCA children;
• Study the effects of genetic variants on the levels 
of biochemical/haematological biomarkers of 
chronic haemolysis;
• Evaluate the putative additional modulating role 
of variants previously identified as stroke risk 
factors by genome-wide associated studies: 
GOLGB1 Y1212C, ENPP1 K173Q and PON1
Q192R.
3. Methodology
• Subjects: 70 SCA children characterized 
according to their CVA degree, by transcranial 
Doppler ultrasound [time-averaged mean of 
maximum velocity (TAMMV) in the middle 
cerebral artery], magnetic resonance imaging 
(MRI) or CT scan;
• Molecular analyses: PCR, PCR-RFLP, Sanger 
sequencing and next-generation sequencing;
• Haplotype reconstruction: Haploview v.2.0,
• Statistical analysis: SPSS v.25.0.
Specific genetic variants and haplotypes in VCAM1 (Table 1), ITGA4 and NOS3 (Table 2) were associated with higher risk or
protection for the occurrence of overt ischemic stroke events or silent cerebral infarcts in children with SCA (Table 3).
5. Conclusion
• We have found significant association between specific variants in genes related with
endothelial adhesion (VCAM1 and ITGA4) and nitric oxide metabolism (NOS3) with several
cerebral vasculopathy outcomes;
• Those genetic factors may be used for the early detection of the SCA children presenting
the highest CVA risk, thus allowing an intensification of their preventive therapeutic
strategies;
• Our findings also provide additional clues on the SCA pathophysiology and uncover
features in these genes that may prove to be crucial as potential therapeutic targets.
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Gene Variant Predicted Effect p
VCAM1
rs1409419_T  LDH <0.001
haplotype 7  LDH <0.001
rs3783613_C  Bilirubin 0.026
Chronic haemolysis biomarker levels also appear to be modulated by VCAM1 and ITGA4 variants (Table 4).
• LDH levels were higher in the presence of VCAM1 promoter rs1409419_T alone as well as of haplotype 7 but lower in 
patients with ITGA4 haplotype 1;
• Total bilirubin levels, on the other hand, were higher in association with VCAM1 rs3783613_C allele.
• VCAM1 promoter haplotype 7 as well as rs1409419_T alone were associated with higher velocity of cerebral blood flow, 
TAMMV (>170 cm/s);  the same was observed for ENPP1 K173Q (rs1044498_A);
• ITGA4 variants rs113276800_A and rs3770138_T were associated with stroke events;
• NOS3 haplotype 5 as well as VNTR 27bp _ 4b allele showed a protective effect for silent cerebral infarcts; haplotype 7 also 
showed a protective effect for cerebral vasculopathy globally.
Variant
VCAM1 haplotypes
1 2 3 4 5 6 7
rs1409419
(T>C)
C C C C C C T
rs3917024
(C>T)
C C C C C T C
rs3917025
(CT>delCT)
CT CT CT CT -- -- CT
rs3783598
(T>G)
T T T T T G T
rs1041163
(T>C)
T T C C T T T
rs3783599
(C>T)
C T C T C C C
Variant
NOS3 haplotypes
1 2 3 4 5 6 7
rs2070744
( C>T)
C C C T T T T
Intron 4 
VNTR*
4a 4b 4b 4a 4b 4b 4c
rs1799983
( T>G)
G G T G G T G
Table 4. VCAM1 and ITGA4 variants’ 
predicted effect on chronic hemolysis 
biomarkers (LDH and total bilirubin).
Table 1. (left) VCAM1 gene promoter haplotypes.
Table 2. (above) NOS3 haplotypes.
Gene Variant Predicted Effect p
ITGA4
haplotype 1:
rs1375493_A
rs35723031_insT
g. 181459459_delTT
 LDH 0.003
Table 3. VCAM1, ITGA4, NOS3 and ENPP1
variants with significant association to cerebral 
vasculopathy.
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*VNTR alleles:  4a = 4 repeats of 27bp; 4b = 5 repeats of 27bp; 4c = 6 repeats of 27bp
